Demupitamab

迪木匹妥单抗

Report date: 2022/01/14 13:23:58

Base Information

Drug NameDemupitamab
Drug Alias Name重组全人源抗人表皮生长因子受体单抗Recombinant full human Anti-EGFR Monoclonal Antibody (Sinocelltech)SCT-200
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionEpidermal growth factor receptor erbB1 antagonists
TargetsEpidermal growth factor receptor erbB1
Therapy Area/IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungHead and Neck Neoplasms +[16] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesSinoCelltech Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesSinoCelltech Ltd
Inactive CompaniesN/A
Active IndicationsSquamous Cell Carcinoma of Head and Neck
Inactive IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungHead and Neck Neoplasms +[15] 

Other Information

ATC CodeN/A
Related LinksN/A